Remove Clinical Trials Remove Document Remove Programs Remove Safety
article thumbnail

FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial

Cannabis Law Report

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. Anthony Durkacz. 1-844-978-3540.

article thumbnail

Veterans and Medical Cannabis: A Comprehensive Guide

MMJ Recs

There are multiple US states with an established state-approved medical marijuana program as well as states permitting the use of cannabinol (CBD) oil – a non-psychoactive component of cannabis – for medical purposes exclusively.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MAPS: Regulatory Publishing Specialist – Remote Position Regulatory Affairs · Any City, Any State, California

Cannabis Law Report

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Compile and submit electronic common technical document (eCTD) submissions to regulatory agencies.

article thumbnail

Position: Atai – Director/Manager Regulatory Affairs (f/m/d)

Cannabis Law Report

Work with the Lead of Regulatory Affairs and the atai Development Team, and with moderate/minimal supervision, with select project teams within subsidiary organizations to develop and oversee program specific regulatory, clinical and development strategies. Represent the company as the Regulatory Affairs expert before U.S.

article thumbnail

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52
article thumbnail

Position -Atai: Director/Manager Regulatory Affairs

Cannabis Law Report

Work with the Lead of Regulatory Affairs and the atai Development Team, and with moderate/minimal supervision, with select project teams within subsidiary organizations to develop and oversee program specific regulatory, clinical and development strategies. Represent the company as the Regulatory Affairs expert before U.S.

article thumbnail

Here’s what you need to know about cannabis research

The Cannigma

However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application. Non-clinical research can help answer questions regarding safety and risk in very powerful ways.